Linked Data API

Show Search Form

Search Results

851533
star this property registered interest false more like this
star this property date less than 2018-02-28more like thismore than 2018-02-28
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
unstar this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading General Practitioners: Postnatal Care more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what proportion of GP practices offer a six week postnatal check-up; and what information his Department holds on the take-up of such checks at those practices. more like this
star this property tabling member constituency Cambridge more like this
star this property tabling member printed
Daniel Zeichner more like this
star this property uin 130296 more like this
star this property answer
answer
star this property is ministerial correction true more like this
star this property date of answer less than 2018-03-08more like thismore than 2018-03-08
unstar this property answer text <p>All general practitioner (GP) practices are expected to provide maternity medical services for their registered patients. Practices may however exceptionally choose to opt out of providing such services e.g. on workload grounds. Practices which choose to opt out will relinquish a proportion of their global sum income – currently 2.1%. It is the responsibility of the lead commissioner locally (NHS England or clinical commissioning groups under delegated agreement) to ensure the patients of opted out practices can continue to access these services e.g. commissioning the service from a nearby alternative practice.</p><p> </p><p>NHS England and the Department do not collate data on the number of practices that have opted out but financial information gives some indication as payments to these practices are reduced to fund the re-commissioning of services. Financial data from 2016/17 suggests that up to four practices out of the 7,523 opted out of maternity medical services<ins class="ministerial">.</ins><del class="ministerial">, which includes the six week postnatal check-up.</del></p><p> </p><p>NHS England and the Department do not collect information on the number of patients who have their post-natal check at their GP practice.</p>
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine more like this
star this property question first answered
less than 2018-03-08T17:05:12.983Zmore like thismore than 2018-03-08T17:05:12.983Z
star this property question first ministerially corrected
less than 2018-04-13T14:03:06.42Zmore like thismore than 2018-04-13T14:03:06.42Z
star this property answering member
4067
star this property label Biography information for Steve Brine remove filter
star this property previous answer version
46101
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine more like this
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
4382
unstar this property label Biography information for Daniel Zeichner more like this
777814
star this property registered interest false more like this
star this property date less than 2017-10-25more like thismore than 2017-10-25
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health more like this
unstar this property answering dept sort name Health more like this
unstar this property hansard heading Prescription Drugs: Prices more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, which prescription drugs had the highest increase in price to the NHS in the last 10 years for which data is available. more like this
star this property tabling member constituency Vale of Clwyd more like this
star this property tabling member printed
Chris Ruane more like this
star this property uin 109619 more like this
star this property answer
answer
star this property is ministerial correction true more like this
star this property date of answer less than 2017-11-03more like thismore than 2017-11-03
unstar this property answer text <p>The table below shows the top five individual medicines <del class="ministerial">and chemicals</del> that have shown the highest increase in <ins class="ministerial">cost</ins> <del class="ministerial">price </del> over the last 10 years for Net Ingredient Cost (NIC) per prescription item <del class="ministerial">and NIC per quantity</del>. Prescription medicines<del class="ministerial">/chemicals</del> have only been included where there was prescribing in both 2006 and 2016.</p><p><ins class="ministerial">For any medicine listed, it does not necessarily mean that the price has increased. For example, the cost per prescription item will be higher if the quantity being prescribed per prescription item has increased.</ins></p><p>This is based on Prescription Cost Analysis (PCA) data. PCA data is based on analysis of all prescriptions dispensed in the community i.e. by community pharmacists and appliance contractors, dispensing doctors, and prescriptions submitted by prescribing doctors for items personally administered in England. PCA data do not cover drugs dispensed in hospitals, including mental health trusts, or private prescriptions.</p><p> </p><p>Costs vary over time due to numerous factors including medicines going off patent and becoming available generically, unlicensed medicines becoming licensed medicines, shortages, the level of competition for generic medicines, as well as centrally agreed pricing schemes such as the Pharmaceutical Price Regulation Scheme.</p><p> </p><p>The Department is working closely with the Competition and Markets Authority on a number of investigations into unwarranted price rises of unbranded generic medicines. Where companies have breached competition law, we will seek damages and invest that money back into the National Health Service.</p><p> </p><table><tbody><tr><td colspan="4"><p>The top five medicines with the highest increase in Net Ingredient<sup>1</sup> Cost per prescription item<sup>2</sup></p></td></tr><tr><td><p>Drug Name</p></td><td><p>2006</p></td><td><p>2016</p></td><td><p>Increase</p></td></tr><tr><td><p>Orfadin_Cap 10mg</p></td><td><p>£5,436.74</p></td><td><p>£20,030.86</p></td><td><p>£14,594.12</p></td></tr><tr><td><p>Cerezyme_I/V Inf 400u Vl (Dry)</p></td><td><p>£18,143.17</p></td><td><p>£30,397.85</p></td><td><p>£12,254.68</p></td></tr><tr><td><p>Chenodeoxycholic Acid_Cap 250mg</p></td><td><p>£88.57</p></td><td><p>£9,580.10</p></td><td><p>£9,491.54</p></td></tr><tr><td><p>Trientine Dihydroch_Cap 300mg (Old)</p></td><td><p>£218.58</p></td><td><p>£5,488.22</p></td><td><p>£5,269.64</p></td></tr><tr><td><p>Sod Benz_Liq Spec 400mg/5ml</p></td><td><p>£361.95</p></td><td><p>£4,352.92</p></td><td><p>£3,990.96</p></td></tr></tbody></table><p>Source: Prescription Cost Analysis</p><p> </p><p>Notes:</p><p> </p><p><sup>1</sup>NIC is the basic cost of a drug. It does not take account of discounts, dispensing costs, fees or prescription charges income, so the amount the NHS spent will be slightly different.</p><p> </p><p><sup>2</sup>Prescriptions are written on a prescription form known as an FP10. Each single item written on the form is counted as a prescription item.</p>
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine more like this
star this property question first answered
less than 2017-11-03T14:32:18.987Zmore like thismore than 2017-11-03T14:32:18.987Z
star this property question first ministerially corrected
less than 2017-12-12T13:55:12.54Zmore like thismore than 2017-12-12T13:55:12.54Z
star this property answering member
4067
star this property label Biography information for Steve Brine remove filter
star this property previous answer version
20077
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine more like this
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
534
unstar this property label Biography information for Chris Ruane more like this
778216
star this property registered interest false more like this
star this property date less than 2017-10-26more like thismore than 2017-10-26
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health more like this
unstar this property answering dept sort name Health more like this
unstar this property hansard heading Tobacco: Packaging more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, what recent assessment he has made of the effect of the introduction of plain cigarette packaging on smoking rates. more like this
star this property tabling member constituency Brentwood and Ongar more like this
star this property tabling member printed
Alex Burghart more like this
star this property uin 110024 more like this
star this property answer
answer
star this property is ministerial correction true more like this
star this property date of answer less than 2017-11-03more like thismore than 2017-11-03
unstar this property answer text <p>The Standardised Packaging of Tobacco Products Regulations 2015 came into force on 20 May 2016. The Government consulted on the introduction of standardised packaging and published an impact assessment, which included benefits to public health. The Government will review these regulations by <ins class="ministerial">2021</ins> <del class="ministerial">2020</del>.</p> more like this
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine more like this
star this property question first answered
less than 2017-11-03T11:41:50.29Zmore like thismore than 2017-11-03T11:41:50.29Z
star this property question first ministerially corrected
less than 2018-03-21T13:09:21.407Zmore like thismore than 2018-03-21T13:09:21.407Z
star this property answering member
4067
star this property label Biography information for Steve Brine remove filter
star this property previous answer version
19960
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine more like this
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
4613
unstar this property label Biography information for Alex Burghart more like this
797514
star this property registered interest false more like this
star this property date less than 2017-11-29more like thismore than 2017-11-29
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health more like this
unstar this property answering dept sort name Health more like this
unstar this property hansard heading Thyroid Gland: Diseases more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, what medicines NHS England has approved for patients with thyroid conditions more like this
star this property tabling member constituency Southampton, Itchen more like this
star this property tabling member printed
Royston Smith more like this
star this property uin 116477 more like this
star this property answer
answer
star this property is ministerial correction true more like this
star this property date of answer less than 2017-12-07more like thismore than 2017-12-07
unstar this property answer text <p><del class="ministerial">For unbranded generics the Government relies on completion to keep prices down which generally works well and has led to low prices of these medicines. We alert the Competition and Markets Authority (CMA) when we believe that competition does not work. In the case of liothyronine, the CMA is currently investigating Concordia’s potential abuse of its dominant position to overcharge the National Health Service for liothyronine.</del></p><p> </p><p><del class="ministerial">In primary care community pharmacies are incentivised to source products at the lowest possible cost by allowing them to retain the medicines margin (the difference between what the NHS reimburses a pharmacy for a product and how much the pharmacy purchases it for) up to £800 million in England. In secondary care, competitive tenders ensure value-for-money to the NHS.</del></p><p><ins class="ministerial"> <p><ins class="ministerial">NHS England is not responsible for approving medicines. The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for ensuring that medicines and medical devices work and are acceptably safe. The National Institute for Health and Care Excellence makes recommendations for the National Health Service on whether medicines and other treatments represent a clinically and cost effective use of NHS resources.</ins></p><p><ins class="ministerial"><strong> </strong></ins></p><p><ins class="ministerial">A list of medicines licensed by the MHRA for the treatment of thyroid conditions is attached. The list is split into two sections because thyroid conditions can be split into either those associated with an overactive thyroid (hyperthyroidism), or an underactive thyroid (hypothyroidism). The list contains only those medicines licensed for overactive and underactive thyroid. It should be noted that not all of the medicines listed will be available on the market at any one time. </ins></p></ins></p>
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine more like this
star this property question first answered
less than 2017-12-07T15:27:25.543Zmore like thismore than 2017-12-07T15:27:25.543Z
star this property question first ministerially corrected
less than 2017-12-07T18:20:31.313Zmore like thismore than 2017-12-07T18:20:31.313Z
star this property answering member
4067
star this property label Biography information for Steve Brine remove filter
star this property attachment
1
unstar this property file name 2017 12 06 Thyroid medicines formatted.xls more like this
star this property title List of thyroid medicines more like this
star this property previous answer version
27995
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine more like this
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
4478
unstar this property label Biography information for Royston Smith more like this